Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
Abstract Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy. Blood samples were obtained before and after immune checkpoint i...
Main Authors: | So Yeon Oh, Soyeon Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-99311-y |
Similar Items
-
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
by: Ja Yoon Heo, et al.
Published: (2019-11-01) -
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
by: Seong-Ho Kang, et al.
Published: (2019-01-01) -
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.
by: Hyungjin Kim, et al.
Published: (2017-01-01) -
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
by: Ju Yeon Lee, et al.
Published: (2016-10-01) -
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
by: Xin Wang, et al.
Published: (2019-02-01)